Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 109Other hematologic neoplasm 59Genitourinary 54Lymphoid 42Gastrointestinal 31Thoracic 28Breast 28Gynecologic 27CNS 21Other solid neoplasm 18Head & Neck 17Myeloid 12Sarcoma 10Plasma cell 8Tumor-Agnostic 6Classical hematology 2NET 1Endocrine 1

Conditions

Sarcoma 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Interleukin-2 × Endocrine × Clear all
NCT04166006 2024-09-19

RaC-Ad

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
51 enrolled
EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡